Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT)

Historical Holders from Q4 2019 to Q3 2025

Symbol
PHAT on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
69,596,826
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
62,337,214
Holdings value
$733,708,081
% of all portfolios
0%
Number of holders
132
Number of buys
70
Number of sells
-39
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Frazier Life Sciences Public Fund, L.P. 8.6% 0% $70,447,299 5,985,327 0% James N. Topper 01 Nov 2025
MILLENNIUM MANAGEMENT LLC 7.1% +20% $59,808,678 +$10,839,417 5,081,451 +22% Millennium Management LLC 30 Sep 2025
Carlyle Group Inc. 4.9% $30,142,485 3,496,808 Carlyle Group Inc. 28 Aug 2025
BlackRock, Inc. 4.6% $14,066,607 3,226,286 BlackRock, Inc. 31 Mar 2025
PRUDENTIAL FINANCIAL INC 0% -100% $8,705 -$24,547,397 2,630 -100% PRUDENTIAL FINANCIAL INC 31 May 2025

Institutional Holders of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 62,337,214 $733,708,081 +$59,003,862 $11.77 132
2025 Q2 57,415,787 $550,618,405 -$26,654,537 $9.59 117
2025 Q1 64,025,009 $401,391,744 -$24,944,522 $6.27 136
2024 Q4 66,610,653 $540,837,976 -$121,495,122 $8.12 141
2024 Q3 72,636,064 $1,312,668,227 +$264,199,549 $18.08 133
2024 Q2 58,109,780 $598,557,394 +$27,856,700 $10.3 113
2024 Q1 55,378,949 $588,085,973 +$14,631,856 $10.62 112
2023 Q4 54,112,686 $503,299,407 +$11,390,968 $9.13 115
2023 Q3 43,760,270 $452,721,621 +$5,267,236 $10.37 109
2023 Q2 42,778,866 $612,591,768 +$176,400,941 $14.32 103
2023 Q1 30,786,694 $219,689,484 +$28,315,357 $7.14 83
2022 Q4 28,212,747 $316,546,824 -$21,719,929 $11.22 83
2022 Q3 30,185,827 $334,342,526 +$38,042,890 $11.08 87
2022 Q2 27,258,631 $230,064,222 +$9,335,400 $8.44 88
2022 Q1 25,654,888 $349,117,442 -$176,036,740 $13.61 74
2021 Q4 28,574,214 $561,954,045 +$49,942,191 $19.67 82
2021 Q3 25,543,470 $819,833,454 +$19,152,056 $32.1 81
2021 Q2 24,918,954 $843,508,479 +$13,169,188 $33.85 76
2021 Q1 24,475,818 $919,193,673 +$1,760,408 $37.56 82
2020 Q4 24,534,138 $815,024,391 +$96,707,884 $33.22 75
2020 Q3 21,632,831 $793,536,439 -$7,640,662 $36.67 57
2020 Q2 21,847,152 $718,752,879 -$3,025,534 $32.91 59
2020 Q1 21,949,381 $565,607,078 +$3,219,839 $25.82 47
2019 Q4 21,809,755 $677,010,000 +$593,409,007 $31.14 40